- Home
- FTDR vs MRUS Comparison
FTDR vs MRUS Comparison
Compare FTDR & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- MRUS
- Stock Information
- Founded
- FTDR 1971
- MRUS 2003
- Country
- FTDR United States
- MRUS Netherlands
- Employees
- FTDR N/A
- MRUS N/A
- Industry
- FTDR Diversified Commercial Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- MRUS Health Care
- Exchange
- FTDR Nasdaq
- MRUS Nasdaq
- Market Cap
- FTDR 4.3B
- MRUS 4.1B
- IPO Year
- FTDR 2018
- MRUS 2016
- Fundamental
- Price
- FTDR $57.26
- MRUS $54.62
- Analyst Decision
- FTDR Hold
- MRUS Strong Buy
- Analyst Count
- FTDR 4
- MRUS 13
- Target Price
- FTDR $54.00
- MRUS $88.54
- AVG Volume (30 Days)
- FTDR 577.9K
- MRUS 736.8K
- Earning Date
- FTDR 08-05-2025
- MRUS 07-31-2025
- Dividend Yield
- FTDR N/A
- MRUS N/A
- EPS Growth
- FTDR 34.69
- MRUS N/A
- EPS
- FTDR 3.08
- MRUS N/A
- Revenue
- FTDR $1,891,000,000.00
- MRUS $54,732,000.00
- Revenue This Year
- FTDR $12.86
- MRUS $75.57
- Revenue Next Year
- FTDR $6.54
- MRUS $31.84
- P/E Ratio
- FTDR $18.43
- MRUS N/A
- Revenue Growth
- FTDR 5.58
- MRUS 42.77
- 52 Week Low
- FTDR $32.95
- MRUS $33.19
- 52 Week High
- FTDR $63.49
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- FTDR 53.99
- MRUS 53.50
- Support Level
- FTDR $58.06
- MRUS $51.78
- Resistance Level
- FTDR $59.95
- MRUS $54.18
- Average True Range (ATR)
- FTDR 1.41
- MRUS 1.56
- MACD
- FTDR -0.33
- MRUS -0.38
- Stochastic Oscillator
- FTDR 53.49
- MRUS 56.60
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.